Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

13.45 +0.87 (+6.92%)
Streaming Delayed Price Updated: 1:46 PM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 Next >
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Elects Kathleen Tregoning to Board of Directors
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments
From Compass Pathfinder Limited
Via Business Wire
News headline image
Small-Cap Medical Stocks: ATAI, CMPS, NDRA, PBM in Focus as U.S. Policy Accelerates Psychedelic Research
Via AB Newswire
News headline image
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants
From Compass Pathfinder Limited
Via Business Wire
News headline image
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces Pricing of $150 Million Public Offering
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Launches Proposed $150.0 Million Public Offering
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Two Investor Conferences in December
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Stifel 2025 Healthcare Conference
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months
From Compass Pathfinder Limited
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.